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Abstract: During childhood, different oral iron preparations are widely used in iron deficiency anemia (IDA) and 
prophylaxis. The purpose of this study was to compare the efficacy of different oral iron preparations in children with IDA. 
Eighty-nine children (age range, 1 to 17 years) with IDA were randomized to receive therapy orally in two divided doses 
of either 5 mg Fe
2+
/kg/day ferrous sulfate (FS group, n = 45) or ferrous fumarate plus zinc and vitamin C (FZ group, n = 
44). Hematological profile and iron status were evaluated at the beginning and on days 15 and 45 of treatment. Mean 
Hb, mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), red cell distribution weight (RDW), and iron 
and ferritin levels were significantly higher in both groups on days 15 and 45 of treatment. Mean changes in Hb were 2.5 
± 1.2 g/dL and 2.1 ± 0.7 g/dL on day 15 (P = 0.295), and 3.9 ± 1.8 g/dL and 3.5 ± 1.2 g/dL on day 45 (P = 0.331) in the 
FS and FZ groups, respectively. Our study suggests that ferrous sulfate and ferrous fumarate plus zinc and vitamin C 
were well tolerated and were highly effective in correcting IDA in children. Ferrous fumarate plus zinc and vitamin C did 
not influence hematologic recovery compared with ferrous sulfate in this group. 
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INTRODUCTION 
Iron deficiency is the most frequent and widespread 
micronutrient deficiency worldwide because it is 
common in developing and developed countries alike 
[1]. Anemia is the most common clinical manifestation 
of iron deficiency. The current treatment strategy for 
iron deficiency anemia (IDA) involves the oral use of 
ferrous sulfate (Fe
2+
) and ferric iron polymaltose 
complex (Fe
3+
) [2, 3]. However, in clinical practice 
bivalent iron salts are preferred over ferric iron 
preparations [4].  
Experimental studies showed that high amounts of 
zinc reduced iron absorption [5]. It is also reported that 
supplementation of zinc together with iron reduced its 
bioavailability in infants, while supplementation with 
only zinc reduced plasma iron levels in adolescents [6, 
7]. However, in another study, if the Fe:Zn ratio was 
2:1, there was no change in the level of iron [8]. On the 
basis of the literature, zinc supplementation alone does 
not appear to have a clinically important negative effect 
on iron status. However, when zinc is given with iron, 
iron indicators do not improve as greatly as when iron 
is given alone [9]. 
Vitamin C supplementation enhances iron absorption, 
although it has a relatively minor effect in individuals 
ingesting normal, balanced diets [10]. Ferrous 
ascorbate provides a significantly higher rise in 
hemoglobin levels in comparison to colloidal iron in 
children [11]. However, studies investigating the effect  
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of vitamin C on ferrous sulfate absorption far 
outnumber those on other iron fortificants, especially in 
meals containing inhibitors of iron absorption [12]. 
Because there are some concerns about their 
interactions in absorption from the intestines [5, 8, 9, 
12, 13], in the present study we aimed to compare the 
effects of zinc sulfate (Zn-S) and vitamin C on 
hematological parameters when ferrous sulfate alone 
and ferrous fumarate, zinc, and vitamin C in 
combination are administered in children with IDA. 
PATIENTS AND METHODS 
A total of 89 consecutive patients who attended the 
Pediatric Hematology/Oncology Outpatient Clinic at 
Eskisehir State Hospital, Turkey, between August 2013 
and January 2014 were enrolled in this open-label 
randomized trial. The study was approved by the 
Ethical Committee of Eskisehir State Hospital. IDA was 
defined as hemoglobin (Hb) below 10.6 g/dL for 
children at or below the age of 2 years, and below 11 
g/dL for children older than 2 years and with a serum 
ferritin value below 12 ng/mL [14, 15]. The children with 
IDA, aged between 1 and 17 years, using simple 
randomization with no restrictions or matching, were 
allocated into the ferrous sulfate (Ferro-Sanol® susp. 
or capsule/Adeka) group or ferrous 
fumarate/zinc/vitamin C (Ferrozinc® susp. or 
capsule/Berko) group. Iron was given at a dose of 5 
mg/kg/day Fe
+2
 by oral route on an empty stomach 
[15]. Children weighing 45 kg or more received two 
capsules a day. The FZ group received zinc 
monohydrate 1.6 mg/kg/day and vitamin C 6.3 
16    Global Journal of Hematology and Blood Transfusion, 2015, Vol. 2, No. 1 Ali Aycicek 
mg/kg/day via iron capsule or syrup. All patients were 
seen at the Outpatient Clinic on days 15 ± 2 and 45 ± 5 
of treatment. At each visit, all patients were examined 
and side effects and all data were recorded. Adherence 
was defined as high if the parents reported drug use on 
6 to 7 days during the week before assessment. 
Children were excluded if they had acute infection, 
had a history of chronic disease [except neurologic 
disease] or parasites, suffered blood loss for any 
reason, or had occult blood in their stools. There was 
no control group of children with IDA followed without 
active treatment as that would have been unethical and 
an infringement of basic human rights. 
Analytical Methods  
Blood samples were collected from a peripheral 
vein into vacutainers containing ethylenediaminete- 
traacetic acid and jelled serum tubes. A hemogram was 
obtained, and ferritin, iron, and total iron binding 
capacity levels were determined using commercial kits 
(Abbott) on the same day. Whole blood count was 
measured by an automated analyzer (Celldyn 3700, 
Abbott, IL, USA). All analyses were performed at a 
single laboratory. 
Statistical Analysis 
Normal distribution of variables was tested using the 
Kolmogorov-Smirnov test. A chi-square test was used 
to assess relationships between categorical 
independent variables. Differences between groups 
were tested by Student’s t-test, while differences 
between pairs of observations were analyzed by paired 
t-test. The data were expressed as mean ± standard 
deviation (SD) and differences were considered 
statistically significant at P < 0.05. Statistical analyses 
were performed using SPSS for Windows Release 11.5 
(SPSS Inc., Chicago, IL, USA). 
RESULTS 
The FS group included 45 patients (male/female: 
23/22) and the FZ group included 44 patients 
(male/female: 24/20); the sex ratio was not significantly 
different between the groups (P = 0.746). The mean 
age of the FS group was 7.8 ± 5.5 years, while that of 
the FZ group was 6.3 ± 6.1 years. Forty-five (51%) of 
them were 1-4 years old. 
The drugs were generally well tolerated but in 6 
patients treatment was ceased due to side effects (3 
patients in the FS group and 3 patients in the FZ
 
group 
were excluded from the study). Adherence to treatment 
was generally good. The adherence rate was 83% in 
the subjects receiving ferrous sulfate, compared with 
84% in those receiving ferrous fumarate plus zinc and 
vitamin C (P > 0.05). No significant differences were 
observed between the groups with respect to the mean 
age, sex, or side effect ratios (P >0.05) (Table 1). 
The hematologic parameters were similar between 
the two study groups at the beginning of the study. The 
patients’ mean Hb (Figure 1), mean corpuscular 
hemoglobin (MCH), mean corpuscular volume (MCV), 
red cell distribution weight (RDW), and iron and ferritin 
levels were significantly higher in both groups on days 
15 and 45 of treatment (Table 2).  
Table 1: Comparison of Side Effects due to Iron Treatment in the Sulfate and Fumarate Groups 
 Baseline  Day 15 Day 45 
 FS FZ FS FZ FS FZ 
Rbc (million/mm3)* 4.5 ± 0.8 4.6 ± 0.8 4.6 ± 0.6 4.9 ± 0.5 5 ± 0.5 4.9 ± 0.7 
Hemoglobin (g/dL)* 8.1 ± 1.5 8.2 ± 1.7 10.6 ± 1.1 10.1 ± 1.4 12 ± 1.4 11.6 ± 1.9 
MCH (pg)* 20 ± 4 18 ± 3 21 ± 1 20 ± 2 23 ± 2 23 ± 3 
MCHC (g/dL)* 30 ± 2 30 ± 2 31 ± 1 30 ± 2 31 ± 1.6 32 ± 1.9 
MCV (fL)* 61 ± 5 61 ± 7 69 ± 4 67 ± 7 73 ± 3 73 ± 5 
RDW (%)* 21 ± 5 21 ± 3 27 ± 11 26 ± 8 21 ± 2 23 ± 5 
Iron (mg/dL)* 13 ± 5 12 ± 5  - - 38 ± 19 31 ± 15 
IBC (mg/dL)* 457 ± 70 453 ± 54 - - 340 ± 68 378 ± 58 
Ferritin (ng/mL)* 3.5 ± 2.7 2.4 ± 2.3 - - 31 ± 18 22 ± 23 
FS, Ferrous sulfate group; FZ, ferrous fumarate plus zinc and vitamin C group. 
*Student’s t test between FS and FZ groups, baseline and on days 15 and 45 (P > 0.05). 
*Paired t test between baseline and on days 15 and 45 (P  0.001). 
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Figure 1: Hemoglobin levels of groups on baseline and on 
days 15 and 45 of therapy. 
Mean red blood cell (RBC) count and mean 
hemoglobin concentration (MCHC) were not 
significantly different (P > 0.05). Mean changes in Hb 
were 2.5 ± 1.2 g/dL and 2.1 ± 0.7 g/dL on day 15 (P = 
0.295) and 3.9 ± 1.8 g/dL and 3.5 ± 1.2 g/dL on day 45 
in the FS and FZ groups, respectively (P = 0.331). No 
patient showed a decrease in Hb in either group.  
The cost of ferrous fumarate plus zinc and vitamin C 
is twice as high as those of ferrous sulfate.  
DISCUSSION 
Current treatment of IDA is successfully performed 
orally with either Fe
2+
 or Fe
3+
 preparations. Moreover, it 
is reported that ferric polymaltose was not as effective 
as ferrous sulfate, although it increased hemoglobin 
and serum iron [16, 17]. The dose of 3-5 mg/kg or 60 to 
120 mg of elemental iron of ferrous sulfate per day for 
a minimum duration of 3 months in adolescents and 
adults, including pregnant women, is recommended 
[18, 19]. Among ferrous preparations, FS remains the 
established and the standard treatment for iron 
deficiency given its acceptable tolerability, high 
effectiveness, and low cost [3]. The absorptive capacity 
of the normal duodenum for iron is essentially 
saturated with about 25 mg of elemental iron in ionic 
form.  
Deficiencies of other trace elements, especially 
zinc, are frequently seen in children with IDA [19, 20]. 
Therefore, in the treatment of patients with IDA, zinc, in 
addition to iron, may be considered [21, 22]. A study 
from Indonesia compared prophylactic treatment 
regimens of 10 mg/d of iron, 10 mg/d of zinc, or both in 
babies starting at 4 months of age and continuing for 6 
months [6]. In that study, the percentage of babies who 
had anemia (Hb<11 g/dL) was higher in those taking 
iron and zinc compared to those taking only iron (46% 
vs. 28%; P<0.05). The authors suggested that 
supplementation of zinc together with iron reduced its 
bioavailability. Another study found that only 
supplemental zinc during 12 weeks in adolescent 
athletes reduced plasma iron levels [7]. In addition, 
experimental studies showed that high amounts of zinc 
reduced iron absorption [5]. However, if the Fe: Zn ratio 
was 2:1, there was no change in the level of iron in 
another study [8]. In order to reduce the possible 
interaction of iron and zinc based on these findings, 
iron and zinc may be used at different times. Because 
there were no differences between the hematological 
data of our 2 groups during treatment, it is seen that 
Table 2: Therapeutic Efficacy of Ferrous sulfate (FS) and Ferrous Fumarate Plus Zinc and Vitamin C (FZ). Data are 
Mean ± SD 
 
FS group* 
(n = 35) 
FZ group* 
(n = 37) 
Difficulty in drinking (n) 2 1 
Stomachache (n) 1 1 
Constipation (n) 3 4 
Diarrhea (n) 0 0 
Nausea and vomiting (n) 1 2 
Stopped receiving treatment due to side effects (n) 3 3 
FS, Ferrous sulfate group; FZ, ferrous fumarate plus zinc and vitamin C group. 
*Differences were not significant. 
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the iron absorption was not affected if iron and zinc 
were given at the same time. 
Vitamin C supplementation enhances iron 
absorption, although it has a relatively minor effect in 
individuals ingesting normal, balanced diets [10]. 
Furthermore, it is reported that ferrous ascorbate 
provides a significantly higher rise in hemoglobin levels 
in comparison to colloidal iron in children such that 
each child received elemental iron 3 mg/kg/day for 12 
wk [11]. Our results showed that ferrous fumarate plus 
ascorbic acid supplementation on an empty stomach 
did not have any positive effect on hematologic 
recovery. However, studies investigating the effect of 
vitamin C on ferrous sulfate absorption far outnumber 
those on other iron fortificants, especially in meals 
containing inhibitors of iron absorption [12, 13]. 
Among ferrous preparations, FS remains the 
established and the standard treatment for iron 
deficiency given its acceptable tolerability, high 
effectiveness, and low cost [2]. Our study showed that 
ferrous fumarate plus zinc and vitamin C drugs were 
significantly more expensive [average 50%] than 
ferrous sulfate. However, this drug did not contribute to 
hematologic recovery and had similar side effects 
compared with ferrous sulfate in children with IDA. This 
form of replacement may not produce fewer problems 
than ferrous sulfate and is not ideal as the initial 
treatment for iron deficiency.  
It was reported that an Hb increase of more than 1 g 
per dL (10 g per L) after iron therapy has been started 
confirms the diagnosis of iron deficiency [22]. Our 
patients’ mean hemoglobin levels increased 2 g/dL with 
both drugs after 15 days. The increase in hemoglobin 
15 days after the beginning of the treatment was not 
significantly higher in the group of children that 
received FS (10.6 ± 1.1 g/dL) compared to the group of 
patients treated with FZ (10.1 ± 1.4 g/dL]. In addition, 
no patient had decreased hemoglobin levels after 
treatment compared to baseline values. 
Anemia affects all population groups, but the most 
susceptible groups are pregnant women and young 
children [18]. Low birth weight infants, young children, 
and women of childbearing age are particularly at risk 
of IDA. Adolescents participating in strenuous training 
are another pediatric subpopulation at risk for iron 
deficiency [14]. The most susceptible groups of our 
child population are young children and adolescents 
who participate in senior high school and national 
higher education entrance examinations in addition to 
participating in strenuous training. 
Although ferrous sulfate is most often 
recommended, patients frequently complain of 
gastrointestinal discomfort, constipation, and bloating, 
as well as stool discoloration, thus making its use 
unacceptable to many. Interestingly, in a randomized, 
controlled trial comparing 3 mg/kg/day of ferrous 
sulfate drops with a placebo in infants, there was no 
significant difference in the frequency of vomiting, 
diarrhea, or fussiness in iron-treated infants compared 
with placebo-treated infants [24]. Our study showed 
that the two drugs had similar types and ratios of side 
effects (totally 19%); in 6% of children treatment was 
ceased due to side effects.  
The limitations of this research were the short 
duration of follow-up and the fact that it was not a 
double-blind trial. In general, if researchers describe a 
trial as double-blind, readers can assume that they 
have avoided bias [25]. The comparison of the drugs is 
most readily accepted if the results are from 
randomized controlled trials [26]. Open-label studies 
are frequently incorporated in the design of randomized 
controlled trials. However, we compared the two 
different oral iron preparations and did not have a 
control group, the results of the patients procured 
during the treatment were compared to their baseline 
and post-treatment values, and each patient was 
assessed with his/her own control in both groups. 
In conclusion, our study suggests that ferrous 
sulfate and ferrous fumarate plus zinc and vitamin C 
are well tolerated and highly effective in correcting IDA 
in children. Ferrous fumarate plus zinc and vitamin C 
did not impact on hematologic recovery compared with 
ferrous sulfate in this group. 
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